# Glyxambi

NDC: 0597-0182
Generic name: empagliflozin and linagliptin
Labeler / Manufacturer: Boehringer Ingelheim Pharmaceuticals, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET, FILM COATED
Routes: ORAL
Marketing started: 20150130

FDA application: NDA206073

## Active ingredients

- EMPAGLIFLOZIN: 10 mg/1
- LINAGLIPTIN: 5 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0597-0182"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0597-0182
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ddbab689-f76c-488c-9613-4168d41dd730